Top Markets
#1 CyberDEX CyberDEX +391.95%
#2 OVERTAKE OVERTAKE +58.99%
#3 Clearpool Clearpool +25.94%
#4 Playnance Playnance +23.93%
#5 deBridge deBridge +22.97%
#6 B3 (Base) B3 (Base) +20.83%
#7 Nillion Nillion +19.56%
#8 AUKI AUKI +19.09%
#9 Codatta Codatta +17.25%
#10 龙虾 (Lobster) 龙虾 (Lobster) +17.03%
Coin of the day
CyberDEX CyberDEX
설정
언어
한국어
통화
USD
테마
Nuformix plc Nuformix plc

Nuformix plc

NFX
주식 순위 #41013
Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes... Nuformix plc, a pharmaceutical company based in the United Kingdom, specializes in developing therapies for fibrotic diseases and cancer, primarily through the innovative strategy of drug repurposing. Its current development portfolio includes NXP001, which has advanced beyond Phase 1 trials for application in oncology supportive care. Additionally, the company is progressing NXP004, a novel variant of Olaparib, currently in its intellectual property generation stage for oncological indications, and NXP002, which is undergoing pre-clinical evaluation for the treatment of idiopathic pulmonary fibrosis. Nuformix also holds an option agreement with Oxilio Ltd. concerning NXP001 for its oncology applications. Established in 2008, the company maintains its operational base in London.
주가
$0.00185055
시가총액
$48.29K
변동 (1일)
-3.55%
변동 (1년)
30.31%
국가
GB
거래 Nuformix plc (NFX)

카테고리

Healthcare
Nuformix plc (NFX)의 매출
Mar 2026 기준 매출 TTM: 0.00
Nuformix plc의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0.00입니다. 2024년에 회사는 0.00의 수익을 올렸으며 이는 2023년의 0.00 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Nuformix plc의 수익 기록 (2014 ~ 2026)
매년 말 매출
연도 매출 변화
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 $65.73K -75.61%
2021 $269.56K -59.39%
2020 $663.79K -16.44%
2019 $794.35K 3,678.32%
2018 $21.02K 0.00%
2017 0.00 -100.00%
2016 $872.91K 181.15%
2014 $310.47K 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH